# GLP-1 Drugs Like Ozempic, Wegovy May Help With Binge Eating Disorder
Glucagon-like peptide-1 (GLP-1) receptor agonists, including Ozempic and Wegovy, show promise in treating binge eating disorder (BED), a mental health condition affecting millions of people. These medications work by slowing gastric emptying and affecting brain signals that control hunger and satiety, potentially reducing the urge to binge eat.
Binge eating disorder involves consuming large amounts of food in short periods while feeling a loss of control. Unlike other eating disorders, people with BED don't typically purge afterward, but the cycle causes emotional distress and often leads to weight gain and health complications. Current treatments include psychotherapy and the FDA-approved medication lisdexamfetamine (Vyvanse), but many patients need additional options.
Recent clinical interest in GLP-1 drugs for BED stems from their dual effects. These medications reduce appetite while also influencing dopamine and serotonin pathways in the brain that regulate mood and food-related decision-making. Early evidence suggests GLP-1s may break the binge-restrict cycle that traps many people with BED.
However, experts emphasize that more research is needed before doctors routinely prescribe these drugs for eating disorders. Most GLP-1 drugs remain FDA-approved only for weight management or type 2 diabetes. Using them off-label for BED requires careful medical supervision, as these medications carry side effects including nausea, vomiting, and pancreatitis risks.
Parents should know that BED often begins in adolescence and frequently coexists with anxiety or depression. If a teen shows signs of binge eating followed by guilt or shame, consulting a mental health professional or pediatrician matters